Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD

NCT01210560 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Autosomal Dominant Polycystic Kidney Disease

Interventions

DRUG: Tolvaptan MR
DRUG: Tolvaptan MR
DRUG: Tolvaptan MR
DRUG: Tolvaptan IR
DRUG: Tolvaptan MR

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.